|
Estonia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Estonia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Estonia.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Estonian pharmaceutical and healthcare industry.
Competitive intelligence, Estonian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Estonian market.
The Estonia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Estonia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Estonian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Estonia to test other views – a key input for successful budgeting and strategic business planning in the Estonian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Estonian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Estonia.
- Exploit The Latest Competitive Estonian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Estonia.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Estonia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Estonia Pharmaceuticals And Healthcare Industry SWOT |
| Estonia Political SWOT |
| Estonia Economic SWOT |
| Estonia Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Estonia – Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| Recent EU Regulatory Developments |
| Directive 75/319/EEC – Article 9 (4) |
| Intellectual Property Regime |
| Pricing Regime |
| Reimbursement Regime |
| Table: Medicinal Products Reimbursed for the Insured (EEK '000) |
| Recent Pricing And Reimbursement Developments |
Chapter - Industry Developments |
| Epidemiology |
| Table: Occurrence Of Malignant Neoplasms In Estonia* |
| Healthcare Sector |
| Table: Recently Approved Generics In Estonia |
| Healthcare Reforms |
| Healthcare Provision |
| Healthcare Funding |
| Table: Main Indicators of HIF's Finances |
| Healthcare Insurance |
| Table: Diagnoses with the Highest Expenditure of Benefits of Medicinal Products |
| Pharmaceutical Sector |
| Manufacturing |
| Recent Company Developments |
| Wholesale Sector |
| Retail Pharmacies |
| Table: Pharmacies And Pharmacy Market Ratios, 2004-2009 |
| Biotechnology |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Estonia – Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Estonia – Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Estonia - Economic Activity |
| Prescription Drug Market Forecast |
| Table: Estonia – Prescription Market Indicators, Historical Data and Forecasts (EEKmn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Estonia – Patented Drug Market Indicators, Historical Data and Forecasts |
| Generic Drug Market Forecast |
| Table: Estonia – Generics Market Indicators, Historical Data and Forecasts |
| OTC Medicine Market Forecast |
| OTC Medicine Market Forecast |
| Table: Estonia - OTC Market Indicators, Historical Data and Forecasts (EEKmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: Estonia – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Estonia – Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Multinational Companies |
| GlaxoSmithKline |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Grindeks (includes Tallinn Pharmaceutical Plant) |
Chapter - Country Snapshot: Estonia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2004 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Estonia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Business Environment Ranking matrix for Q209, Estonia fell from fourth to seventh position out of the 20 regional markets surveyed, although it is still better placed than its Baltic neighbours, namely Latvia and Lithuania. While Estonia’s overall pharmaceutical score remained virtually unchanged from the previous quarter, as well as above average for the region, its attractiveness is severely constrained by the small population, high out-of-pocket expenditure on drugs (which is threatened by the current economic conditions) and the cost-containment leanings of its public healthcare system. Nevertheless, the demand for drugs will rise over the forecast period owing to an increased need for modern medicines and healthcare service improvements, while the recent increase in the VAT on pharmaceuticals should also serve to boost values. In fact, Statistics Estonia recently revealed that retail sales of pharmaceutical goods and cosmetics increased 12% year-on-year (y-o-y) in December 2008, despite a 9% y-o-y decline in retail sales.
In the light of the above, we forecast that the country’s pharmaceutical market, valued at US$280mn in 2008 at consumer prices, will grow at a compound annual growth rate (CAGR) of 5.1% in US dollar terms - or 8.1% in local currency terms – through 2013, to reach US$359mn. Generics presently represent less than 34% of the total market value, although the need for cost-containment will likely boost their share to 37% by the end of the forecast period. Over-the-counter (OTC) medicines will be negatively impacted by the current economic conditions, although the latter parts of the forecast period should see some improvements, despite strong price competition in the retail sector.
In the meantime, the government continues to implement measures to reduce the expenditure by the country’s Health Insurance Fund (HIF). In February 2009, the authorities announced that the system of sick leave compensation would be changed, with the aim of saving EEK465mn (EUR29mn) through the elimination of compensation for the first day of sick leave. Around the same time, The Baltic Times reported that the government agreed on an EEK8bn (EUR5.1bn) total budget reduction package across ten of its ministries.
The above situation will be compounded by the expected negative real GDP growth forecast (of -6.4% for the year), which will mark the worst recession since 1992. We expect widespread deleveraging throughout the economy to plunge private consumption growth to -6.0%, while the destruction of external demand will also send export growth into negative territory. Over the long term, a marked recovery is not likely until 2011 and, from then on, we forecast Estonian economic growth to settle at a trend average of 4.0-5.0%. In fact, industrial output growth collapsed to -21.7% in December 2008, its lowest point since at least January 1995. The pharmaceutical industry seems to, however, mostly been immune to such difficulties, with the production of pharmaceutical products increasing by 8% y-o-y in January 2009, although imports continue to meet much of the local demand. Exports remain of basic generic and active pharmaceutical ingredients (API) varieties, which are increasingly in demand across the cash-strapped European public healthcare systems.
|
Estonia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |